12-month data set up Pfizer DMD gene therapy for Phase III, but SAEs may give Sarepta safety edge

Pfizer believes encouraging long-term efficacy data and recently installed protocols for mitigating adverse events will help the pharma advance its DMD gene therapy into Phase III testing within the next few months as it ramps up its manufacturing capabilities. But another SAE for the program appears to signal that a Sarepta-Roche gene therapy also slated to enter Phase III this year still has an advantage on safety.

The updated

Read the full 680 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE